ISU Abxis Company Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares ISU Abxis Company Limited with three other
companies in this sector in South Korea:
sales of 18.09 billion Korean Won [US$16.07 million]
of which 85%
was The clinical trial agent),
(12.10 billion Korean Won [US$10.75 million]
Cellumed Co Ltd
(21.61 billion Korean Won [US$19.19 million]
ISU Abxis Company Limited reported sales of 19.46 billion Korean Won (US$17.28 million)
December of 2017.
increase of 2.1%
versus 2016, when the company's sales were 19.05 billion Korean Won.
This was the third consecutive year of growth at ISU Abxis Company Limited.
Sales of Antibody Medicine saw an increase
3.8% in 2017, from
18.74 billion Korean Won to 19.45 billion Korean Won.
Not all segments of ISU Abxis Company Limited experienced an increase in sales in 2017:
sales of Other fell 95.8% to 13.37 million Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).